Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epitinib Phase Ib in Advanced Solid Tumors
NCT02590952Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Oct 2011
- Primary completion
- Apr 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epitinib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Incidence of all types/grades of adverse events. Started Oct 2011; status: completed.
02
Drugs
epitinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02590952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590952.